View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 12, 2021

FDA clears Zymo Research’s collection device for Covid-19 testing

The US Food and Drug Administration (FDA) has granted 510(k) clearance to Zymo Research’s DNA/RNA Shield Collection Tube as a Class II medical device.

The US F ood and Drug Administration (F DA) has granted 510(k) clearance to Zymo Research ’s DNA/RNA Shield Collection Tube as a Class II medical device.

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

The latest development aids in the usage of the tube as an in-vitro diagnostic (IVD) device for Covid-19 testing.

The device is the first F DA-cleared technology that can inactivate the virus and preserve the SARS-CoV-2 RNA.

Effective inactivation of the SARS-CoV-2 virus permits the safe handling, transportation and storage of the sample, ensuring the safety of frontline healthcare and laboratory staffs.

The viral RNA is stabilised at ambient temperature for prolonged periods for robust analysis via downstream RT-PCR.

Zymo Research business development vice-president Dr Marc Van Eden said: “DNA/RNA Shield had a proven track record in various infectious disease applications prior to the current pandemic, facilitating its rapid adoption and deployment in the early stages of the Covid outbreak.

“The 510(k) is the result of the F DA’s active collaboration with Zymo Research in bringing this technology to the forefront of current testing and future surveillance efforts.”

The product comprises a tube filled with the company’s proprietary DNA/RNA Shield transport medium, which ensures the SARS-CoV-2 RNA’s stability during specimen transportation and storage for up to 28 days at ambient temperatures.

The media may be kitted with a swab, sputum collection kit or as a tube alone.

Zymo Research noted that the technology is compatible with upper and lower respiratory specimens taken from people suspected of having SARS-CoV-2.

F urthermore, specimens collected and stored in a collection tube are well-suited for use with appropriate molecular diagnostic tests.

Last November, Zymo Research received the CE IVD mark for Quick-DNA/RNA Viral MagBead Kit for distribution to the European Union common market.

It was designed for high-throughput purification from biological samples that are stored in the company’s DNA/RNA Shield used for sample collection, nucleic acid preservation and inactivation of pathogens.

Related Companies

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network